ALKS Quote, Financials, Valuation and Earnings

Assertio Holdings, Inc. has a net margin of 12.83% compared to Alkermes Plc's net margin of -88.08%. Alkermes Plc's return on equity of 14.82% beat Assertio Holdings, Inc.'s return on equity of -29.06%.

Alkermes Plc has a consensus price target of $43.71, signalling upside risk potential of 25.45%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $38.25 which suggests that it could grow by 99.12%. Given that Assertio Holdings, Inc. has higher upside potential than Alkermes Plc, analysts believe Assertio Holdings, Inc. is more attractive than Alkermes Plc.

Alkermes Plc has a beta of 0.402, which suggesting that the stock is 59.843% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.642%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $384.5M, which are larger than Assertio Holdings, Inc. quarterly revenues of $13.5M. Alkermes Plc's net income of $49.3M is higher than Assertio Holdings, Inc.'s net income of -$11.9M. Notably, Alkermes Plc's price-to-earnings ratio is 24.16x while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.96x versus 4.52x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Avadel Pharmaceuticals Plc has a net margin of 12.83% compared to Alkermes Plc's net margin of 0.03%. Alkermes Plc's return on equity of 14.82% beat Avadel Pharmaceuticals Plc's return on equity of -0.34%.

Alkermes Plc has a consensus price target of $43.71, signalling upside risk potential of 25.45%. On the other hand Avadel Pharmaceuticals Plc has an analysts' consensus of $21.83 which suggests that it could grow by 0.89%. Given that Alkermes Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Avadel Pharmaceuticals Plc.

Alkermes Plc has a beta of 0.402, which suggesting that the stock is 59.843% less volatile than S&P 500. In comparison Avadel Pharmaceuticals Plc has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.791%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Avadel Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $384.5M, which are larger than Avadel Pharmaceuticals Plc quarterly revenues of $77.5M. Alkermes Plc's net income of $49.3M is higher than Avadel Pharmaceuticals Plc's net income of $20K. Notably, Alkermes Plc's price-to-earnings ratio is 24.16x while Avadel Pharmaceuticals Plc's PE ratio is 299.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.96x versus 8.56x for Avadel Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 12.83% compared to Alkermes Plc's net margin of 0.91%. Alkermes Plc's return on equity of 14.82% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Alkermes Plc has a consensus price target of $43.71, signalling upside risk potential of 25.45%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Alkermes Plc has higher upside potential than Amicus Therapeutics, Inc., analysts believe Alkermes Plc is more attractive than Amicus Therapeutics, Inc..

Alkermes Plc has a beta of 0.402, which suggesting that the stock is 59.843% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $384.5M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Alkermes Plc's net income of $49.3M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Alkermes Plc's price-to-earnings ratio is 24.16x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.96x versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 12.83% compared to Alkermes Plc's net margin of 47.99%. Alkermes Plc's return on equity of 14.82% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Alkermes Plc has a consensus price target of $43.71, signalling upside risk potential of 25.45%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $314.00 which suggests that it could grow by 20.33%. Given that Alkermes Plc has higher upside potential than Krystal Biotech, Inc., analysts believe Alkermes Plc is more attractive than Krystal Biotech, Inc..

Alkermes Plc has a beta of 0.402, which suggesting that the stock is 59.843% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.540, suggesting its less volatile than the S&P 500 by 46.017%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $384.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. Alkermes Plc's net income of $49.3M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Alkermes Plc's price-to-earnings ratio is 24.16x while Krystal Biotech, Inc.'s PE ratio is 38.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.96x versus 20.22x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.